Published in Cancer Chemother Pharmacol on May 16, 2007
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol (2010) 1.82
Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy? Cell Death Differ (2008) 1.73
Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis (2009) 1.72
Delving deeper: MCL-1's contributions to normal and cancer biology. Trends Cell Biol (2012) 1.60
Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs (2011) 1.39
Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res (2010) 1.35
BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist Updat (2007) 1.33
Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs (2010) 1.32
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol (2010) 1.26
BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem (2010) 1.23
Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem (2009) 1.11
Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res (2008) 1.11
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer (2011) 1.10
VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia. Mol Ther (2010) 1.08
BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Mol Cancer Ther (2008) 1.07
Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. Br J Haematol (2011) 1.04
Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review. Expert Opin Ther Pat (2011) 1.04
The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens. Oncotarget (2010) 1.01
An optically pure apogossypolone derivative as potent pan-active inhibitor of anti-apoptotic bcl-2 family proteins. Front Oncol (2011) 1.01
Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine. Int J Cancer (2010) 1.00
Novel small-molecule inhibitors of Bcl-XL to treat lung cancer. Cancer Res (2013) 0.99
Oleanolic acid initiates apoptosis in non-small cell lung cancer cell lines and reduces metastasis of a B16F10 melanoma model in vivo. PLoS One (2011) 0.96
Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis. Cell Cycle (2011) 0.94
Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem (2010) 0.94
Small-molecule Bcl-2 antagonists as targeted therapy in oncology. Curr Oncol (2008) 0.89
RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells. Oncotarget (2014) 0.89
Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer. Neoplasia (2011) 0.87
Single-agent obatoclax (GX15-070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells. Oral Oncol (2013) 0.86
Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy. J Immunol (2014) 0.85
Molecular interactions of prodiginines with the BH3 domain of anti-apoptotic Bcl-2 family members. PLoS One (2013) 0.83
OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis. PLoS One (2013) 0.83
Obatoclax impairs lysosomal function to block autophagy in cisplatin-sensitive and -resistant esophageal cancer cells. Oncotarget (2016) 0.83
Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage. Mol Oncol (2014) 0.81
Small-molecule inhibitors reveal a new function for Bcl-2 as a proangiogenic signaling molecule. Curr Top Microbiol Immunol (2011) 0.81
Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells. J Exp Clin Cancer Res (2015) 0.80
Targeted drugs in small-cell lung cancer. Transl Lung Cancer Res (2016) 0.77
Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis. Oncotarget (2016) 0.77
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A (2007) 4.92
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol (2009) 4.07
Stat3 regulates genes common to both wound healing and cancer. Oncogene (2005) 2.80
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene (2003) 2.54
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol (2010) 2.53
Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res (2006) 2.41
Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood (2008) 2.18
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res (2008) 2.17
Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst (2011) 1.92
A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 1.77
Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther (2005) 1.75
Direct repression of the Mcl-1 promoter by E2F1. Oncogene (2002) 1.60
Proteomic contributions to personalized cancer care. Mol Cell Proteomics (2008) 1.46
Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. BMC Genomics (2006) 1.38
Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res (2010) 1.35
Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther (2007) 1.30
JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther (2011) 1.29
Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol Cancer Ther (2003) 1.16
Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res (2012) 1.16
Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. Oncol Rep (2007) 1.12
Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity. J Proteome Res (2010) 1.10
Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A (2013) 1.09
The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res (2010) 1.08
Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance. J Clin Invest (2013) 1.08
MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int J Oncol (2009) 1.07
Genetic and pharmacologic inhibition of mTORC1 promotes EMT by a TGF-β-independent mechanism. Cancer Res (2013) 1.07
Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions. J Biol Chem (2012) 1.06
Dasatinib in solid tumors. Expert Opin Investig Drugs (2010) 1.06
Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. Biochem Pharmacol (2010) 1.05
Functional interaction of Aurora-A and PP2A during mitosis. Mol Biol Cell (2007) 1.01
EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer. J Clin Oncol (2005) 1.01
TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells. Proc Natl Acad Sci U S A (2014) 0.99
Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. Hematology Am Soc Hematol Educ Program (2005) 0.99
Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer (2008) 0.98
Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling. PLoS One (2010) 0.98
Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur J Cancer Prev (2012) 0.98
GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. ACS Chem Biol (2013) 0.97
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer (2014) 0.95
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Mol Syst Biol (2013) 0.93
Use of penetrating peptides interacting with PP1/PP2A proteins as a general approach for a drug phosphatase technology. Mol Pharmacol (2005) 0.93
Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. Pharmacogenomics (2002) 0.92
Src inhibitors in lung cancer: current status and future directions. Clin Lung Cancer (2010) 0.91
Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J Thorac Oncol (2014) 0.91
cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth. J Clin Invest (2016) 0.89
Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells. Cancer Biol Ther (2009) 0.89
An essential role for Stat3 in regulating IgG immune complex-induced pulmonary inflammation. FASEB J (2011) 0.88
Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. J Immunother (2013) 0.87
Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors. J Med Chem (2012) 0.86
The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Autophagy (2010) 0.86
Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: case report and review of literature. Lung Cancer (2004) 0.84
Anti-metastatic and anti-tumor growth effects of Origanum majorana on highly metastatic human breast cancer cells: inhibition of NFκB signaling and reduction of nitric oxide production. PLoS One (2013) 0.83
Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature. J Pharm Pract (2012) 0.83
A miniaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsies. J Proteome Res (2013) 0.81
Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer. J Thorac Oncol (2014) 0.81
Effects of IFN-gamma and Stat1 on gene expression, growth, and survival in non-small cell lung cancer cells. J Interferon Cytokine Res (2007) 0.81
The NAD+ synthesis enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT1) regulates ribosomal RNA transcription. J Biol Chem (2013) 0.81
IPEP: an in silico tool to examine proteolytic peptides for mass spectrometry. Bioinformatics (2008) 0.80
Azaindole derivatives are inhibitors of microtubule dynamics, with anti-cancer and anti-angiogenic activities. Br J Pharmacol (2013) 0.80
Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer. Chest (2005) 0.79
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors. Cancer Chemother Pharmacol (2011) 0.78
Intranuclear delivery of a novel antibody-derived radiosensitizer targeting the DNA-dependent protein kinase catalytic subunit. Int J Radiat Oncol Biol Phys (2011) 0.78
Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling. Biochem Pharmacol (2010) 0.78
TNFRSF10B polymorphisms and haplotypes associated with increased risk of death in non-small cell lung cancer. Carcinogenesis (2013) 0.78
Non-canonical IKKs, IKKϵ and TBK1, as novel therapeutic targets in the treatment of non-small cell lung cancer. Expert Opin Ther Targets (2013) 0.77
The potential benefits of BIM in the further pursuit of biomarker discovery in cancer therapeutics. Cancer Discov (2011) 0.76
The ethical imperative of risk disclosure in research: the answer is always yes. Am J Bioeth (2014) 0.75
Healthcare providers' knowledge and attitudes about rapid tissue donation (RTD): phase one of establishing a rapid tissue donation programme in thoracic oncology. J Med Ethics (2013) 0.75